• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Pfizer Ltd.
    01 Sep 2025
    5107.50
    -1.64%
    'Want The Answer Now': Trump Wants Pfizer, Other Drugmakers To Justify Covid Vaccine Success
    'Want The Answer Now': Trump Wants Pfizer, Other Drugmakers To Justify Covid Vaccine Success
    NDTV Profit
    Trump claimed that companies like Pfizer had shown him "extraordinary" results but were not sharing them with the public.
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. has gained 25.55% in the last 6 Months
    logo
    Supriya Lifescience Ltd.
    01 Sep 2025
    High Gain High Volume
    726.20
    5.42%
    Supriya Lifescience Eyes 33-35% Ebitda Margins In FY26 Led By New Products, US Expansion
    Supriya Lifescience Eyes 33-35% Ebitda Margins In FY26 Led By New Products, US Expansion
    NDTV Profit
    The company has already launched a new anaesthetic product in the first quarter of FY26, targeting a $300 million market.
    Copy LinkShare onShare on Share on Share on
    Supriya Lifescience .. has an average target of 800.00 from 1 broker.
    logo
    Anlon Healthcare Ltd.
    28 Aug 2025
    134.51
    1.17%
    Dr Agarwal's Eye Hospitals to merge with parent Dr Agarwal's Health Care
    Business Line
    As per the scheme, AHCL will issue and allot 23 new equity shares of face value of 1 each, for every two equity shares of face value of 10 held by eligible shareholders in AEH
    Copy LinkShare onShare on Share on Share on
    Anlon Healthcare Ltd. has gained 47.81% in the last 1 Year
    logo
    Pfizer Ltd.
    28 Aug 2025
    5107.50
    -1.64%
    Why getting Covid-19 vaccine is likely to be more complicated this year?
    Business Line
    The US Food and Drug Administration has OK'd new shots from Pfizer, Moderna and Novavax, but the approvals came with some new caveats
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. has gained 25.55% in the last 6 Months
    logo
    SMS Pharmaceuticals Ltd.
    28 Aug 2025
    Dividend
    292.14
    2.37%
    SMS Pharmaceuticals shares zoom 10% on clean USFDA inspection report
    Business Standard
    SMS Pharmaceuticals shares rose 10 per cent after it received an Establishment Inspection Report with a No Action Indicated from the USFDA
    Copy LinkShare onShare on Share on Share on
    Promoters unpledged 5.11% of shares in last quarter. Total pledge stands at 32.49% of promoter holdings
    logo
    Cipla Ltd.
    27 Aug 2025
    1575.80
    -0.15%
    Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US
    Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US
    NDTV Profit
    The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    Cipla recalls over 20k packs of inhalation drug in US
    Business Line | 27 Aug 2025
    logo
    Sai Life Science Ltd.
    26 Aug 2025
    913.65
    2.12%
    Sai Life Sciences Bulk Deal: TPG Exits Via Rs 2,675-Crore Sale; Societe Generale, Goldman Sachs Acquire
    Sai Life Sciences Bulk Deal: TPG Exits Via Rs 2,675-Crore Sale; Societe Generale, Goldman Sachs Acquire
    NDTV Profit
    IIFL Capital Services Ltd., Kotak Securities Ltd. and Jefferies India Pvt. were the bookrunners for the deal.
    Copy LinkShare onShare on Share on Share on
    Sai Life Science Ltd. has gained 29.24% in the last 6 Months
    Sai Life Sciences slips 5% on heavy volumes; should you buy, sell or hold?
    Business Standard | 26 Aug 2025 1 more
    Sai Life Sciences Block Deal: TPG Likely To Exit Via Rs 2,640-Crore Stake Sale
    NDTV Profit | 25 Aug 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    26 Aug 2025
    1321.70
    -0.08%
    Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access
    Business Standard
    Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    Dr Reddy's launches drug for treatment of chronic constipation
    Business Line | 26 Aug 2025 1 more
    Dr Reddy's launches novel drug for chronic constipation management
    Business Standard | 26 Aug 2025
    logo
    Aurobindo Pharma Ltd.
    26 Aug 2025
    1119.20
    -0.86%
    Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys
    Business Standard
    CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    logo
    Indoco Remedies Ltd.
    26 Aug 2025
    301.95
    0.07%
    Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price
    Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price
    NDTV Profit
    Nirmal Bang values the company at 11x Jul-27E EV/Ebitda and maintain Hold rating on Indoco Remedies, resulting in a target price of Rs 310.
    Copy LinkShare onShare on Share on Share on
    Indoco Remedies Ltd. has gained 31.19% in the last 6 Months
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd